Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors

Antibody–drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that combine a monoclonal tumor-surface-receptor-targeting antibody with a highly cytotoxic molecule payload bonded through specifically designed cleavable or non-cleavable chemical linkers. One such tumor surface rece...

Full description

Bibliographic Details
Main Authors: Blair McNamara, Michelle Greenman, Nicole Pebley, Levent Mutlu, Alessandro D. Santin
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Molecules
Subjects:
antibody–drug conjugate
gynecologic malignancy
HER2
ERBB2
chemotherapy
cervical cancer
Online Access:https://www.mdpi.com/1420-3049/28/21/7389

Similar Items

Similar Items